Optellum, AI Lung Cancer Diagnosis Innovator, Secures $14M Series A Funding to Accelerate Expansion

Lead investor Mercia, alongside Intuitive Ventures and Black Opal, invests in Optellum’s pioneering AI-powered lung-health technology Optellum, an Oxford-based medtech company that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round. The investment will enable Optellum to scale its base, operations, and commercial launches in the UK and USA; accelerate research and development; and expand its platform into personalized therapy decisions by integrating imaging data with molecular data, robotics, and liquid biopsies. This funding round was led by Mercia, with additional investors Intuitive Ventures (Sunnyvale, CA, USA) and Black Opal Ventures (New York, NY, USA). Existing investors, including St John’s College in the University of Oxford, IQ Capital, and the family office of Sir Martin & Lady Audrey Wood, also participated in this round. Lung cancer is the most common type of cancer and the leading cause of cancer deaths in the world. Approximately 150,000 people in the United States and 1.8 million people worldwide die from lung cancer each year. The current worldwide five-year survival rate is 20 percent, primarily because most patients are diagnosed after symptoms have appeared and the disease has progressed to an advanced stage (Stage III or IV). In contrast, the survival rate for small tumors treated at Stage 1A is up to 90 percent. This disparity highlights a cri...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: AI/Machine Learning Health IT Company Healthcare IT Black Opal Ventures GE Healthcare Health IT Funding Health IT Fundings Health IT Investment Intuitive Ventures IQ Capital Jason Pesterfield Johnson & Johnson Lung Cancer Lung Sc Source Type: blogs